Stonex Financial cut shares of Harvard Bioscience (NASDAQ:HBIO – Free Report) from a moderate buy rating to a hold rating in a research report sent to investors on Wednesday morning,Zacks reports.
HBIO has been the topic of a number of other research reports. Benchmark lifted their price objective on shares of Harvard Bioscience from $6.00 to $7.50 and gave the stock a “speculative buy” rating in a research report on Wednesday, August 12th. Zacks Research started coverage on Harvard Bioscience in a research note on Tuesday, November 3rd. They set a “hold” rating on the stock. Weiss Ratings upgraded shares of Harvard Bioscience from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Finally, StoneX lowered shares of Harvard Bioscience from a “speculative buy” rating to a “hold” rating in a research report on Wednesday. One investment analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Harvard Bioscience currently has a consensus rating of “Hold” and an average target price of $6.75.
Read Our Latest Stock Report on Harvard Bioscience
Harvard Bioscience Price Performance
Harvard Bioscience (NASDAQ:HBIO – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.27. Harvard Bioscience had a negative net margin of 13.20% and a negative return on equity of 43.94%. The company had revenue of $22.20 million during the quarter, compared to analysts’ expectations of $21.80 million. On average, research analysts predict that Harvard Bioscience will post -2.44 EPS for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Harvard Bioscience stock. Meros Investment Management LP purchased a new stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 182,992 shares of the medical instruments supplier’s stock, valued at approximately $1,125,401. Meros Investment Management LP owned 4.02% of Harvard Bioscience as of its most recent filing with the SEC. 80.87% of the stock is owned by institutional investors.
About Harvard Bioscience
Harvard Bioscience, Inc. (NASDAQ: HBIO) develops, manufactures and supplies specialized tools, equipment and consumables used in biomedical research, drug discovery and related life science applications. Its products support work in areas such as cell biology, electrophysiology, gene delivery, organ-on-chip research and preclinical studies. The company’s portfolio includes laboratory instruments, tissue and organ perfusion systems, electrophysiology equipment, cell and molecular biology products, and related consumables.
Read More
- Five stocks we like better than Harvard Bioscience
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
